How Cipher Pharmaceuticals Is Developing Products for Dermatological Disorders
Source: Dan Levy for The Life Sciences Report  (11/4/15)
Skin disorders encompass a broad class of medical indications, from psoriasis to melanoma. Many companies focus on developing treatments for specific dermatological indications, but few have been able to build product portfolios with the range of therapeutic and consumer products currently marketed by Cipher Pharmaceuticals. In this interview with The Life Sciences Report, Shawn Patrick O'Brien, president and CEO of Cipher, describes his company's ongoing efforts to address unmet needs in dermatology. More >

Sierra Metals Sees Organic Growth Leading to a Billion-Dollar Valuation
Source: Kevin Michael Grace of The Gold Report   (11/2/15)
Since 2010, Sierra Metals has managed to continually increase production at its Bolivar and Cusi mines in Mexico and its Yauricocha mine in Peru while increasing reserves. Even better, all three mines are part of huge land packages barely explored. In this interview with The Gold Report, Sierra Metals President and CEO Mark Brennan explains how he has centralized and rationalized company operations, how he is modernizing production and how he intends to grow Sierra internally to become a large-cap producer with a billion-dollar-plus market cap. More >

Aethlon Medical's Biofiltration Platform Tackles Everything from Ebola to Cancer: CEO James Joyce
Source: Gail Dutton of The Life Sciences Report  (10/28/15)
Aethlon Medical Inc. has pioneered a novel biofiltration platform that was used effectively against Ebola in 2014. Now this broad-spectrum platform is being tested against cancer and other life-threatening diseases. Aethlon CEO James "Jim" Joyce tells The Life Sciences Report how this device is helping transform modern healthcare. More >

OTC Strategy Supports Cobra Venom Pipeline in Asia and North America: Nutra Pharma's Rik Deitsch
Source: Gail Dutton of The Life Sciences Report  (10/21/15)
A strategy of over-the-counter sales helps derisk Nutra Pharma Corp. as it advances a therapeutic pipeline based on cobra toxin. In this interview with The Life Sciences Report, CEO Rik Deitsch elaborates how he plans to grow the company through distribution of Nutra Pharma's pain medications in India, China, Canada and the U.S., and how therapies based on the toxin can address a variety of autoimmune diseases. More >

Cleaner Water and Stronger Aluminum Drive Clean TeQ's Future
Source: Kevin Michael Grace of The Gold Report  (10/21/15)
Australia's Clean TeQ Holdings Limited, a long-time industry leader in environmental remediation, has recently partnered with China's largest power generator to treat waste water with its unique continuous-ion technology. This technology also allows Clean TeQ to extract metals from minerals and industrial waste, but as Clean TeQ Chairman Sam Riggall explains in this interview with The Gold Report, the company is also on track to open the world's first standalone scandium mine, and has already inked collaboration agreements with the end users that will use this currently rare metal to make aluminum lighter and stronger. More >

Delivering the Triple Whammy that Makes Stem Cell Therapies Commercially Viable: Cynata Therapeutics' Ross Macdonald
Source: Gail Dutton of The Life Sciences Report  (10/14/15)
Stem cell therapies have been slowed by high production costs, batch-to-batch variability and limited seed material. Ross Macdonald, CEO of Cynata Therapeutics, tells The Life Sciences Report how his company's innovative manufacturing methods can generate robust, consistent and inexpensive stem cells, and how this technology is likely to accelerate the commercialization of stem cell therapies worldwide. More >

Breakthrough Potential: BriaCell Therapeutics Takes Its Cancer Vaccine to the Next Level
Source: Gail Dutton of The Life Sciences Report  (9/30/15)
Immuno-oncology has the potential to not only transform medicine, but also to become a multibillion-dollar market for a drug developer with the right team and the right compound. In this interview with The Life Sciences Report, BriaCell Therapeutics Corp. executives Joseph Wagner, Charles Wiseman and Saeid Babaei describe their company's new therapeutic, which has generated stunning results in early trials, making "breakthrough" designation by the FDA a realistic possibility. More >

Sunridge Is Now Good to Go at Its Asmara VMS Project in Eritrea
Source: Kevin Michael Grace of The Gold Report  (9/24/15)
It's been a very active decade filled with milestones for Sunridge Gold, and now following the September signing of a comprehensive permitting agreement with its partner, the government of Eritrea, the Canadian junior is set to begin production in 2016. In this interview with The Gold Report, President and CEO Michael Hopley discusses the riches of his company's copper, gold, zinc and silver deposits and looks forward to becoming as successful as Nevsun has been. More >

The Promise of Plants in Pharmaceutical Production: iBio's Robert Erwin
Source: Gail Dutton of The Life Sciences Report  (9/9/15)
The growing need for recombinant proteins for vaccines and therapeutics is causing the biotech industry to look beyond vat fermentation and cell cultures for protein expression systems that, like iBio Inc.'s iBioLaunch technology, can increase yields quickly, safely and inexpensively. In this interview with The Life Sciences Report, iBio's President Robert L. (Bob) Erwin describes the iBioLaunch technology and what it offers to drug developers and investors. More >

NexGen Energy: A Bold New Uranium Venture for a World in Short Supply
Source: Peter Byrne of The Energy Report  (9/8/15)
NexGen Energy Ltd. has a strong, well-focused uranium project located in the cornucopia of the Athabasca Basin. Without hype, CEO Leigh Curyer and Corporate Development Manager Travis McPherson, part of an experienced team of "pure-play uranium professionals," make the case for investment in a project with obvious legs. More >

Resource Capital Funds Backs Callinex's Strategy near HudBay Operations
Source: Kevin Michael Grace of The Gold Report  (9/3/15)
Manitoba's Flin Flon Greenstone Belt has yielded VMS discoveries resulting in dozens of mines. Callinex Mines has been a big part of that success for almost a century and believes it has the properties that will become the district's latest winners. In this interview with The Gold Report, Callinex President and CEO Max Porterfield explains how high-grade assays and proximity to existing producers could lead to his company discovering the ore that HudBay will soon need. More >

Disrupting Treatment of Cardiovascular Disease with Epigenetics: Resverlogix CEO Donald McCaffrey
Source: Gail Dutton of The Life Sciences Report  (8/26/15)
The evidence is mounting: Resverlogix Corp.'s first-in-class, epigenetics-based drug candidate has demonstrated its ability to significantly reduce major adverse cardiac events (MACE)—death, heart attacks, strokes and heart failure, particularly in diabetic patients—in three consecutive clinical trials. That, company President and CEO Donald McCaffrey tells The Life Sciences Report, is why RVX-208 will likely be a blockbuster. More >

Quaterra Resources Has the Property, the People and the Partner for Large-Scale Nevada Copper Mining
Source: Kevin Michael Grace of The Gold Report  (8/20/15)
Few copper juniors hold the promise that Quaterra Resources does. Its 51 square miles in Nevada contains a past-producing mine. Its management is savvy and well seasoned. And it is backed by the strength of global player Freeport-McMoRan Nevada LLC, a wholly owned subsidiary of Freeport Minerals Corporation, which in turn is a wholly owned subsidiary of Freeport-McMoRan Inc. In this interview with The Gold Report, President and CEO Steven Dischler tells us why he believes his company's Bear project could open up a whole copper district. More >

The Next Phase for MultiStem: Athersys' Gil Van Bokkelen
Source: George S. Mack of The Life Sciences Report   (8/12/15)
Regenerative medicine is surging toward the mainstream, and Athersys Inc. is riding the crest. Potential safety concerns surrounding cell therapies have been largely addressed, and now the efficacy of the company's MultiStem platform in several massive markets, including stroke, heart attack and acute pulmonary disease, are ready to be tested. As the company advances its portfolio of programs, Chairman and CEO Gil Van Bokkelen tells The Life Sciences Report about the promise that MultiStem holds for both patients and investors. More >

Biota Pharmaceuticals' Direct-Acting Antivirals Target the Root Cause of Viral Conditions
Source: Gail Dutton of The Life Sciences Report  (7/14/15)
Direct-acting antiviral therapies are poised to become a major disruptive technology in treatment for viruses, including human rhinovirus and human papillomavirus. Dr. Joseph M. Patti, CEO of Biota Pharmaceuticals Inc., tells The Life Sciences Report about the novel antiviral therapies in his company's pipeline that address the cause of viral conditions, rather than merely the symptoms. More >

Pershing Gold NASDAQ Uplist Is Part of Larger Resource Expansion and Production Push
Source: Peter Byrne of The Gold Report  (7/9/15)
Catalysts can drive stock prices, and Pershing Gold has had quite a few lately, including a stock split, uplisting to NASDAQ and an updated resource estimate on the Relief Canyon Mine in Nevada. And in this interview with The Gold Report, CEO Steve Alfers says there is still more to come for the near-term producer. An economic study and more resource updates are planned by the end of the year. More >

Proven and Productive: BNK Petroleum Pumps Growth from Shale Properties
Source: Tom Armistead of The Energy Report  (7/7/15)
BNK Petroleum Inc. operates on some very productive property in the Oklahoma oil and gas shale and is making progress on developing shale resources in Europe. As oil prices strengthen, company President and CEO Wolf Regener describes how his seasoned management team has positioned the company to grow again. In this interview with The Energy Report, Regener lifts the veil on BNK's activities both at home and abroad. More >

A Clear Vision for a Turnaround: Ron Najafi of NovaBay Pharmaceuticals
Source: George S. Mack of The Life Sciences Report  (6/24/15)
What a difference just nine months can make. NovaBay Pharmaceuticals Inc. has a materially derisked business strategy with new products coming rapidly to market, big-time distribution partners in place and new shareholders embracing the stock following a drug trial disappointment in mid-August 2014. In this interview with The Life Sciences Report, company founder, President and CEO Dr. Ramin "Ron" Najafi talks about the turnaround and how he is steering the product portfolio toward a hockey-stick sales growth curve. More >

Atna Resources' Pipeline Puts It in Position to Soar
Source: Kevin Michael Grace of The Gold Report  (6/18/15)
When James Hesketh became president and CEO of Atna Resources in 2009, the company had plenty of promise but no gold production. Today, Atna has two producing mines—Briggs in California and Pinson in Nevada, with excellent prospects for expansion. Yet Atna shares can be had for only a dime. In this interview with The Gold Report, Hesketh explains how he intends to bring his company up to 100,000 ounces a year using primarily internal cash flow and how a rising gold price would reward investors with multiples. More >

It's All in the Delivery: How RXi Pharmaceuticals' Innovative Platform Will Transform Medicine
Source: BTV/The Life Sciences Report  (5/29/15)
Inhibition—developing therapies that can suppress certain disease mechanisms—is a major thrust in modern biotech. With its unique RNA interference delivery platform, spun out from the mind of a Nobel laureate, CEO Dr. Geert Cauwenbergh tells The Life Sciences Report about the transformational treatments RXi Pharmaceuticals Corporation has in the pipeline, therapies that can both enrich lives and investors' portfolios. More >